Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.67 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.58 |
| ▸ | KDR | P35968 | 3/20 | 0.53 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.49 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | RAF1 | P04049 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14083599 | 0.89 | TRPV1 (0.67) | TRPV1GRM4KDRTMPRSS4MEN1 | |
| SCHEMBL14083371 | 0.89 | TRPV1 (0.61) | TRPV1GRM4 | |
| SCHEMBL14083354 | 0.88 | TRPV1 (0.79) | TRPV1 | |
| SCHEMBL14083208 | 0.86 | GRM4 (0.56) | TRPV1GRM4KDRTMPRSS4 | |
| SCHEMBL14083367 | 0.86 | TRPV1 (0.64) | TRPV1TMPRSS4MEN1KMT2A | |
| SCHEMBL14083484 | 0.84 | TRPV1 (0.76) | TRPV1GRM4KDR | |
| SCHEMBL14083352 | 0.84 | TRPV1 (0.61) | TRPV1GRM4MEN1HTTKMT2A | |
| SCHEMBL14083939 | 0.83 | GRM4 (0.66) | TRPV1GRM4KDRMEN1HTT | |
| SCHEMBL14083368 | 0.83 | TRPV1 (0.61) | TRPV1KDR | |
| SCHEMBL14083348 | 0.83 | TRPV1 (0.59) | TRPV1GRM4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | TRPV1, TRPA1, TRPV2 | TRPV1 1/4885GRM4 362/4885KDR 2604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.